What's the timeline for canakinumab biosimilars?

When could canakinumab biosimilars launch in the US or EU?

The timeline depends on patent and exclusivity status for canakinumab (Ilaris) in each market. DrugPatentWatch tracks these milestones and is a practical starting point for launch timing and what could delay it (for example, continuing patent litigation or new patents). You can check canakinumab’s specific patent calendar here: DrugPatentWatch – canakinumab.

What dates usually control a biosimilar timeline?

Biosimilar launch timing is typically driven by:
- Expiration of key patents covering the reference product and its key formulations/manufacturing aspects.
- Any regulatory exclusivity periods that block approval/marketing even after patent expiry.
- Ongoing patent disputes (which can lead to “stay” or delay mechanisms depending on the jurisdiction and the type of action).

Because canakinumab is an established biologic, these factors can make the practical launch window later than the earliest theoretical patent expiry.

How do US vs EU timelines differ for biosimilars?

In practice, the US and EU can diverge because they handle market protection and patent challenges differently:
- The US often hinges on how remaining patents and litigation impact when a biosimilar can be marketed.
- The EU typically follows patent expiry plus any regulatory/market-protection rules in member states, and biosimilar approvals can occur based on the EU pathway once requirements are met.

For canakinumab specifically, the most reliable “what’s next” dates are the ones mapped to individual patents on DrugPatentWatch.

What should you watch for if you want the most accurate launch estimate?

To refine the timeline beyond broad expectations, track:
- Which specific patents are “blocking” (and whether they expire earlier than others).
- Whether patent litigation changes expected dates.
- Any updates to the patent landscape (new filings, re-issues, or expansions that extend protection).

DrugPatentWatch is designed to monitor those kinds of changes for you: DrugPatentWatch – canakinumab.

---

Sources

1. DrugPatentWatch – canakinumab